ResearcherUniversity of OxfordActive in the last 2 years
Daniel Llwyd Hughes
Matched on ORCID iD 0000-0002-7167-1325; OpenAlex author ID A5080327459, A5103931910. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 5
- Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
- Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized therapy. Co-author DOI 10.1126/sciadv.adm9071↗
- Predicting Early Disease Recurrence of Pancreatic Cancer following Surgery: Determining the Role of NUDT15 as a Prognostic Biomarker. Co-author DOI 10.3390/curroncol29040206↗
- Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1038/s41416-020-01120-z↗
- TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. Co-author DOI 10.1053/j.gastro.2021.04.044↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Frances W. Willenbrock · 4 shared papers, 2021–2024 · strength 0.63
- Paper Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized thera… DOI 10.1126/sciadv.adm9071↗
- Paper Predicting Early Disease Recurrence of Pancreatic Cancer following Surgery: Determining the Role of NUDT15 as a Prognos… DOI 10.3390/curroncol29040206↗
- Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
- Somnath Mukherjee · 4 shared papers, 2021–2024 · strength 0.63
- Paper Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized thera… DOI 10.1126/sciadv.adm9071↗
- Paper Predicting Early Disease Recurrence of Pancreatic Cancer following Surgery: Determining the Role of NUDT15 as a Prognos… DOI 10.3390/curroncol29040206↗
- Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
- Eric E. O’Neill · 3 shared papers, 2021–2024 · strength 0.43
- Paper Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized thera… DOI 10.1126/sciadv.adm9071↗
- Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
- Paper TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. DOI 10.1053/j.gastro.2021.04.044↗
- Michael Eyres · 2 shared papers, 2021–2024 · strength 0.31
- Paper Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized thera… DOI 10.1126/sciadv.adm9071↗
- Paper TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. DOI 10.1053/j.gastro.2021.04.044↗
- Simei Go · 1 shared paper, 2024 · strength 0.22
- Tim Maughan · 2 shared papers, 2021 · strength 0.21
- Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
- Paper TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. DOI 10.1053/j.gastro.2021.04.044↗
- Eric O’Neill · 1 shared paper, 2022 · strength 0.20
- Christopher Mark Jones · 1 shared paper, 2021 · strength 0.12
- Chris N Hurt · 1 shared paper, 2021 · strength 0.12
- Zenobia D’Costa · 1 shared paper, 2021 · strength 0.10
- Simone Lanfredini · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.